UBS reiterates Amneal Pharmaceuticals stock Buy rating on HRT growth
UBS reiterated a Buy rating on Amneal Pharmaceuticals (AMRX) with a $25.00 price target, citing growth in its hormone replacement therapy patch franchise. The stock is up 94% over the past year. Amneal reported Q2 earnings of $0.30 per share, beating estimates, and revenue of $796.2 million. Oppenheimer initiated coverage with an Outperform rating and $27.00 target, noting the impact of its Kashiv acquisition.
How this was made
The 30-second read
Why it matters
Analyst upgrades provide a new catalyst that could move the stock higher in the short term.
Market read
Analyst upgrades and acquisition news create a fresh, actionable catalyst for AMRX.
What to watch
Potential regulatory hurdles for the acquisition and competition in the HRT patch market.
Background
The article recaps Amneal's recent earnings beat and adds fresh analyst coverage and price target updates.
Ticker impact
UBS reiterated a Buy rating with a $25 price target and Oppenheimer initiated coverage with an Outperform rating, highlighting the $750M Kashiv acquisition and recent earnings beat.
likely upward pressure as investors price in the higher target and acquisition synergies
The new coverage and higher target are fresh analyst actions not previously reported, providing a concrete catalyst for the stock.
Market effects
Positive signal for the broader pharma/biosimilars sector as the acquisition may boost pipeline confidence.
U.S. biotech equities may see modest gains from the analyst upgrades.
Limited to investors tracking U.S. biotech and specialty pharma stocks.
Counterpoint
If the Kashiv integration faces delays, the upside may be overstated.
Key entities
- AnalystUBS
Reiterated Buy rating and raised price target to $25.
- AnalystOppenheimer
Initiated coverage with Outperform rating and $27 target.
- Acquisition TargetKashiv
$750 million acquisition to expand biosimilars platform.
